You Jingjing, Hodge Chris, Hoque Monira, Petsoglou Constantinos, Sutton Gerard
Save Sight Institute, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
School of Optometry and Vision Science, UNSW Sydney, Sydney, NSW, Australia.
Clin Ophthalmol. 2020 Oct 12;14:3195-3210. doi: 10.2147/OPTH.S265701. eCollection 2020.
Human platelet products have emerged as an alternative treatment for a range of ocular surface diseases such as dry eye and corneal ulceration. With significant therapeutic potential and increasing popularity, this study aimed to conduct a systematic review to detail the various production methods involved in generating platelet-derived products, compare and analyze clinical findings across available studies, and disseminate the relative advantages, limitations, and challenges of using platelet products to treat ocular surface disease. Thirty-eight clinical studies were identified, excluding studies conducted in animals and non-English language. Studies reported clinical outcomes, which included ocular surface disease index, best-corrected visual acuity, and corneal fluorescein staining. Most clinical studies reported improved patient signs and symptoms with an increasing variety of human platelet products including platelet rich plasma eye drops, human platelet lysate and platelet gels. However, due to variations in production methods, and study designs as well as confusing terminology, it was suggested that characterization of platelet products is needed for proper evaluation across studies.
人血小板制品已成为治疗一系列眼表疾病(如干眼症和角膜溃疡)的替代疗法。鉴于其巨大的治疗潜力和日益普及,本研究旨在进行系统综述,详细阐述生成血小板衍生产品所涉及的各种生产方法,比较和分析现有研究中的临床发现,并传播使用血小板制品治疗眼表疾病的相对优势、局限性和挑战。共确定了38项临床研究,排除了在动物身上进行的研究和非英文研究。研究报告了临床结果,包括眼表疾病指数、最佳矫正视力和角膜荧光素染色。大多数临床研究报告称,使用包括富血小板血浆滴眼液、人血小板裂解物和血小板凝胶在内的各种人血小板制品后,患者的体征和症状有所改善。然而,由于生产方法、研究设计的差异以及术语的混淆,建议对血小板制品进行表征,以便在各项研究中进行适当评估。